The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a study for patients who have been previously treated for B-ALL. The purpose of this
study is to determine the safety and feasibility of CART-19 cells to the patients with
relapsed and refractory CD19+ B-ALL.
Phase:
Phase 1
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborator:
The Beijing Pregene Science and Technology Company, Ltd.